|
Patent landscape, scope, and claims summary: |
United States Patent 9,115,113 (HBV) Claims and US Patent Landscape Analysis
US Patent 9,115,113 is a US-listed patent built around a broad structural genus defined as “Formula II” compounds (plus salts) followed by narrower genus/species claim fallbacks, then composition and method-of-use claims aimed at treating hepatitis B virus (HBV) infection and reducing HBV viral load, including combination regimens with classes of antivirals and immunomodulators. The claim set is high-coverage on chemical substituent diversity and broad in pharmacologic use framing, but its enforceable scope in practice will depend on (i) how narrowly the “Formula II” drawing actually maps to a specific disclosed scaffold in the specification and (ii) whether the asserted embodiments overlap prior art antiviral scaffolds and HBV treatment combinations.
This analysis is limited to the claims text provided; it does not evaluate prosecution history, citation lists, or Orange Book/FDA dossier linkages because those inputs are not included.
What is USP 9,115,113 claiming: core “Formula II” genus and fallback claim structure?
Executive snapshot
- Core claim: Claim 1 defines a compound of “Formula II” with extensive options for heteroatom placement (X, Y/Z), linker chemistry (L¹, L²), and substituent variability (R¹, R², R³, Rˣ, Rʸ, IV, m, n, p, q).
- Claim fallbacks: Claims 2–10 tighten specific definitional knobs (Y/Z identity, specific L¹ = C(O)NH, IV = halo, constrained Rʸ patterns, constrained fused/bridged ring realizations, constrained Rᶻ).
- Product form: Claim 14 covers a pharmaceutical composition with pharmaceutically acceptable carrier.
- Use: Claims 15–25 cover HBV treatment methods and combination therapy, with lists of permitted agent classes and example molecules.
Claim 1: breadth mechanics
Claim 1 is a structural Markush-style genus with:
- Variable core heteroatoms:
- X is C or N.
- One of Y or Z is N, the other is C.
- Variable substituent architecture:
- L¹ is either an amide-like unit “--C(O)NR¹--” or sulfonamide-like unit “--SO₂NR¹--”.
- L² is a bivalent linker selected from alkylene/cycloalkylene oxy/amine substituted patterns:
- “--(C1-3 alkylene)-”
- “--(C3-7 cycloalkylene)-”
- “--(C1-3 alkylene)q-O--(C1-3 alkylene)q-”
- “--(C1-3 alkylene)q-NH--(C1-3 alkylene)q-”
- Variable aryl/heteroaryl substituted termini:
- R¹: H or C1–6 alkyl.
- R²: C1–6 alkyl, halo, polyhaloalkyl, cycloalkyl/heterocycloalkyl, aryl/heteroaryl, alkylene-aryl combinations.
- R³: same classes as R² with additional H.
- Variable substitution patterns for Rˣ, Rʸ, and IV:
- Rˣ: includes halo, cyano, nitro, haloalkyl and multiple “(L²)q-C(=O)R² / (L²)qCO₂R³ / (L²)q-C(=O)N(R³)₂” patterns.
- Rʸ: permits the most diverse chemistry (alkyl/halo/nitro/cyano; aryl/heteroaryl; cyclic and linked aryl/cycloalkyl; plus carbonyl formation when two Rʸ co-occupy the same carbon).
- IV: permits many of the same functional groups as Rˣ/Rʸ families (alkyl/halo/cyano/nitro; protected acyl/esters/carbonyl/thiocarbonyl/amide-like patterns; aryl and linked aryl/cycloalkyl patterns; m is 1–3 for certain ring-linked constructs, and q is 0–1 for presence/absence of the additional linker insertion).
Claim 1: what matters for infringement
Enforcement against a competitor compound will turn on:
- Does the accused compound fall inside Formula II, with the same allowable set for X and Y/Z (N/C placement).
- Does it match L¹ (amide-like vs sulfonamide-like).
- Do its substituents match the permitted set for Rˣ and IV (including permitted carbonyl/ester/amide-like moieties and heteroaryl substitution).
- Do its ring-closure features match the Rʸ fusion/bridging/carbony lization rules (adjacent fused ring vs bridged bicyclic chain vs same-carbon C(=O) formation).
- Does it meet the specified integer ranges for m (1–3), n (0–3), p (1–3), q (0 or 1) as actually instantiated in the competitor structure.
Claims 2–10: narrower “knob turning” fallbacks
- Claim 2 locks Y = N and Z = C.
- Claim 3 constrains L¹ to “--C(O)NH--” (R¹ fixed to H).
- Claim 4 constrains IV to halo.
- Claim 5 narrows Rʸ to only selected members (H, alkyl, halo, and selected (L²)q-alkoxy, (L²)q-carboxylate, and alkylene-aryl options).
- Claim 6 narrows Rʸ patterns by requiring same-carbon closure to form C(O).
- Claim 7 narrows Rʸ adjacent fusion closure to rings that are C3–10-cycloalkyl or phenyl.
- Claim 8 narrows non-adjacent Rʸ closure to bridged bicyclic group where the bridge is a C1–3-alkyl chain.
- Claim 9–10 narrow Rᶻ:
- Claim 9: Rᶻ is C1–6 alkyl/halo/(L²)q-OR³/C3–7 cycloalkyl.
- Claim 10: further restricts to halo or C1–6 alkyl only.
Claims 11–13: formula-specific dependent forms
- Claim 11 adds a “Formula III” variant with m = 0, 1, or 2.
- Claim 12 adds a “Formula IV” variant with m = 0, 1, or 2.
- Claim 13 enumerates multiple structural sub-classes (images not provided in text, but claim language indicates several specific structures or families).
Claim 14: formulation
- Composition claim is standard: compound of claim 1 (or salt) + pharmaceutically acceptable carrier.
Claims 15–25: HBV method-of-use and combination therapy
- Claim 15: administer therapeutically effective amount to treat HBV infection.
- Claims 16–25: add combination and specific agent lists, including:
- Claim 16: at least one additional therapeutic agent selected from:
- HBV polymerase inhibitor
- interferon
- viral entry inhibitor
- viral maturation inhibitor
- BAY 41-4109
- reverse transcriptase inhibitor
- TLR-agonist
- AT-61 and AT-130
- Claim 17: reverse transcriptase inhibitor list includes classic nucleos(t)ide analogs and broad HIV/HBV-like list (e.g., lamivudine, entecavir, tenofovir, adefovir, etc.).
- Claim 18: TLR agonists includes SM360320 and AZD 8848.
- Claims 19–21: interferon class and specific IFN alpha/beta/lambda/gamma options, including pegylated IFN alpha-2a and alpha-2b.
- Claim 22: add HBV vaccine or nucleoside HBV inhibitor or interferon combinations.
- Claim 23: vaccines include Recombivax HB and Engerix-B (among others).
- Claim 24: reduces HBV viral load via compound alone or with reverse transcriptase inhibitor, plus HBV vaccine.
- Claim 25: includes monitoring viral load until undetectable.
How strong are the patentability and validity exposures implied by this claim scope?
1) Chemical genus size increases prior-art collision risk
Claim 1 authorizes extensive substitution diversity across:
- halogenation and polyhaloalkyl,
- multiple carbonyl-containing side groups and linkers,
- aryl and heteroaryl options,
- ring closure behavior for Rʸ (fusion, bridging, carbonyl formation on same carbon),
- L¹ switching between amide and sulfonamide-like chemistry.
That breadth typically increases the probability that one or more individual claim embodiments are anticipated by or obvious over earlier patents/publications covering similar scaffolds with the same substituent space.
2) Markush fallbacks help, but narrower dependent claims may still overlap prior art
Claims 2–10 tighten certain parameters, which can salvage novelty/obviousness if the prior art is close but fails to match those locked features. However, because those locks are relatively definitional (Y/Z identity, IV = halo, L¹ = C(O)NH, Rʸ closure constraints) rather than a unique stereochemical motif or rare substituent set, prior art that already uses those common features can still defeat novelty.
3) Method-of-use claims are “high-level” HBV treatment statements with combination expansions
- Claim 15 is a straightforward “treat HBV” administration claim. That tends to be broad and not tied to a specific pharmacokinetic exposure, dose, regimen timing, or biomarker threshold other than Claim 25’s “undetectable” monitoring approach.
- Claim 16 enumerates very broad additional agent classes plus specific named small molecules and named TLR agonists (SM360320, AZD 8848) and compounds (BAY 41-4109, AT-61, AT-130). This also increases risk that the combination aspects are not novel if those regimens were already standard in the art.
4) Combination claims may be vulnerable where prior art already discloses co-administration
Even if the compound is novel, combination claims can be anticipated if prior art already teaches co-administration of the same classes of HBV drugs with analogous antiviral candidates, or if the specific named co-agents are already used in HBV regimens.
Which claim elements drive infringement risk for competitors: structure-to-claim mapping
Structure-limiting elements
The strongest “gates” for whether an accused compound infringes:
- Whether it matches the allowed core heteroatom identity: X in {C, N} and Y/Z as N/C complement.
- Whether L¹ is restricted to amide-like “--C(O)NR¹--” or sulfonamide-like “--SO₂NR¹”.
- Whether the allowed linker L² matches the permitted oxy- or amino-alkylene patterns.
- Whether the substitution pattern realizes Rˣ and IV substituent families (including carbonyl, ester, amide-like, thio-carbonyl, and aryl/heteroaryl-linked options).
- Whether ring closure rules for Rʸ (fused ring vs bridged bicyclic bridge vs same-carbon C(O) formation) apply.
Patent scope implication
If the specification includes only a narrow subset of the Markush embodiments, claim breadth can still be enforceable, but validity can be challenged on enablement/best mode-type grounds, written description, or lack of support depending on how the disclosure is actually written. Those analyses require specification text, which is not provided here.
What patents protect the HBV use and how do dependent method claims affect enforceability?
Method claims: direct inducement and label-driven enforcement
- Claim 15 supports direct infringement by administering the compound for HBV treatment.
- Claims 16–25 expand to combinations. In practice, this is the hook for:
- induced infringement where prescribers follow combination regimens implied by clinical guidance or promotional materials, and
- contributory infringement where combination use is encouraged.
Combination range: broad
The dependent method claims cover multiple combination categories and explicitly name:
- HBV polymerase inhibitors (class),
- interferons including pegylated IFN alpha,
- reverse transcriptase inhibitors including tenofovir, entecavir, lamivudine, adefovir, etc.,
- viral entry/maturation inhibitors (class),
- TLR agonists SM360320 and AZD 8848,
- BAY 41-4109,
- AT-61 and AT-130.
That breadth increases enforcement reach but also makes validity more contestable if those combinations are routine.
Which “generic entry” risks exist based on this claim set?
Chemical composition patents can block generics if structure overlaps
A generic risk scenario typically requires both:
- chemical structural overlap within Formula II (or one of dependent narrowed zones), and
- a valid, enforceable composition claim (Claim 14) and/or method claim that aligns with actual generic labeling and commercial use.
Method-of-use claims can be circumvented by label design
Even if the compound is structurally covered, competitors can often manage risk by avoiding labeled HBV indications tied to the patent’s method claims, or by focusing on different patient subsets, dosing regimens, or excluded combinations.
Claim 25’s “undetectable HBV virus” monitoring limitation is a potential narrowing element, but method claims are still often enforced even when monitoring is inherent in standard HBV practice.
How does USP 9,115,113 compare with typical HBV patent estates: likely strengths and weaknesses
Strengths
- High chemical coverage via expansive substituent language, increasing the chance that a competitor’s lead candidate is within the claimed genus.
- Multiple dependent claims create fallback positions that can align with specific real-world embodiments.
Weaknesses
- Large genus size tends to create stronger prior-art and obviousness attack surfaces.
- HBV method-of-use claims are broadly framed with extensive list-based combination agents, which is vulnerable if those combinations were already known.
Commercial and regulatory angle: what would matter for a real enforcement strategy
Enforcement levers
- If a competitor compound fits Formula II, Claim 14 can be used to target sales of the compound formulation.
- If competitor labeling includes HBV treatment and potentially combination regimens, Claims 15–25 can be used to support inducement theories tied to prescribing practices and labeling language.
Risk-based conclusion
Because the chemical claim language is broad, the strongest commercial relevance is whether a specific competitor molecule falls within the Markush-defined parameter set. If it does, the estate’s method claims likely add leverage for combination regimens, but do not replace the need for chemical coverage.
Key claim-by-claim “criticality” map (what to watch in litigation)
| Claim |
Scope type |
Practical purpose |
Critical watchpoints |
| 1 |
Broad chemical genus |
Core infringement anchor |
Mapping accused structure to Formula II including L¹, L², Rˣ, Rʸ closure, IV, and integer parameters |
| 2 |
Chemical narrowing |
Salvage novelty/coverage |
Y/Z placement must match (Y=N, Z=C) |
| 3 |
Chemical narrowing |
Salvage coverage with fixed L¹ |
L¹ must be exactly C(O)NH (R¹ = H) |
| 4 |
Chemical narrowing |
Salvage coverage |
IV must be halo |
| 5 |
Chemical narrowing |
Narrow substituent class |
Rʸ allowed set only |
| 6 |
Chemical narrowing |
Lock ring closure chemistry |
Same-carbon Rʸ creates C(O) |
| 7 |
Chemical narrowing |
Lock fused ring realization |
Adjacent closure gives C3–10 cycloalkyl or phenyl |
| 8 |
Chemical narrowing |
Lock bridged bicyclic bridge type |
Bridge must be C1–3 alkyl chain |
| 9–10 |
Chemical narrowing |
Restrict Rᶻ |
halo or C1–6 alkyl (Claim 10) |
| 11–12 |
Formula variants |
Additional coverage bands |
m parameter in Formula III/IV must match |
| 13 |
Specific structures |
Tight species |
Exact enumerated structures must match |
| 14 |
Composition |
Formulation sales |
Accused product must contain claim 1 compound (or salt) |
| 15 |
Method HBV treatment |
Induce/prescribe hook |
“Treat HBV” use matches accused product labeling or off-label practice |
| 16–24 |
Combination methods |
Expand enforcement to multi-drug regimens |
Whether the combination matches the claimed agent classes and named molecules; also whether prior art already teaches such combos |
| 25 |
Monitoring/endpoint |
Adds a functional outcome |
“Undetectable HBV virus” monitoring window and routine practice alignment |
Key Takeaways
- USP 9,115,113 is built on a broad Formula II chemical genus with extensive substituent variability, reinforced by narrower dependent claims that lock specific structural “knobs” (heteroatom placement, linker type, IV=halo, and Rʸ ring-closure patterns).
- The estate includes composition and broad HBV treatment method-of-use claims, with combination regimens that cover major HBV therapeutic classes and specific named agents (BAY 41-4109, SM360320, AZD 8848, AT-61, AT-130, plus nucleos(t)ide analogs and interferons/vaccines).
- In enforcement, chemical structure mapping to Formula II and its dependent constraints is the primary determinant of infringement. The method claims expand leverage for HBV combination prescribing but introduce higher validity risk because the combination framework is broad and label-independent.
FAQs
-
Does Claim 14 (composition) expand infringement beyond method claims if a generic labels differently?
Yes if the generic product contains a compound that falls within Claim 1 (or covered salts), Claim 14 can target sales/formulation even with label carve-outs to method-of-use.
-
Which dependent claims most directly constrain a competitor’s chemical structure?
Claims 2–4 (Y/Z, L¹ = C(O)NH, IV = halo) and Claims 6–8 (specific Rʸ closure modes), plus Claims 9–10 (tight Rᶻ limitation).
-
How do Claims 7 and 8 affect design-around strategies?
They restrict the allowed ring-closure outcomes for fused/bridged systems. Competitors can design outside those closure forms while staying potentially close to the base scaffold, depending on how Formula II is satisfied.
-
Do the method claims require a specific dose, schedule, or biomarker threshold?
Claim 15 is dose-agnostic (“therapeutically effective amount”). Claim 25 adds an endpoint concept (“undetectable” HBV virus) but does not prescribe a specific dose or interval in the claim text provided.
-
What combination agents named in Claim 16–24 create the most obviousness/prior-use vulnerability?
The explicitly named agents and classes that are common in HBV care (interferons including pegylated forms, nucleos(t)ide reverse transcriptase inhibitors such as tenofovir/entecavir/lamivudine, plus TLR agonists SM360320 and AZD 8848) heighten risk that combination regimens were already known.
References (APA)
No external sources were provided in the prompt, and no additional bibliographic materials are cited.
More… ↓
⤷ Start Trial
|
